The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1414
April 15, 2013
View Complete Issue         Table of Contents 2019 
Teduglutide Injection (Gattex) for Short Bowel Syndrome
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Teduglutide Injection (Gattex) for Short Bowel Syndrome
April 15, 2013 (Issue: 1414)
The FDA has approved teduglutide (te due’ gloo tide; Gattex – NPS), a recombinant DNA analog of glucagon-like peptide-2 (GLP-2), for treatment of short bowel syndrome (SBS) in adults who are dependent on parenteral support.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Teduglutide Injection (Gattex) for Short Bowel Syndrome
Article code: 1414b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.